🧪
hypothesis

Epigenetic Age Acceleration Moderates the Amyloid-to-Tau Conversion Cascade — A "Clock Threshold" Model of AD Progression

Hypothesis

Epigenetic Age Acceleration Moderates the Amyloid-to-Tau Conversion Cascade — A "Clock Threshold" Model of AD Progression

Concise Statement: There exists a critical threshold of epigenetic age acceleration (~4–6 years above chronological age) above which the transition from amyloid deposition to tau propagation becomes dramatically accelerated, explaining t.
🧬 MAPT🎯 Composite 34%💱 $0.49▲9.1%active
neurodegeneration
EvidencePending (0%)📖 5 cit🗣 1 debates 5 support 2 oppose
✓ All Quality Gates Passed
Mechanistic 0.42 (15%) Evidence 0.17 (15%) Novelty 0.30 (12%) Feasibility 0.00 (12%) Impact 0.00 (12%) Druggability 0.15 (10%) Safety 0.25 (8%) Competition 0.31 (6%) Data Avail. 0.54 (5%) Reproducible 0.20 (5%) KG Connect 0.24 (8%) 0.343 composite
☰ Compare⚔️ Duel⚛️ Collide
📄 Export LaTeX
arXiv PreprintNeurIPSNature MethodsPLOS ONE
📖 Export BibTeXinteract with this hypothesis
Composite34%

🧪 Overview


Concise Statement: There exists a critical threshold of epigenetic age acceleration (~4–6 years above chronological age) above which the transition from amyloid deposition to tau propagation becomes dramatically accelerated, explaining the highly variable lag between amyloid positivity and clinical symptom onset across individuals.

...

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

flowchart TD
    A["MAPT/Tau Protein<br/>Microtubule Stabilizer"]
    B["CDK5/GSK3B Activation<br/>Kinase Dysregulation"]
    C["Tau Hyperphosphorylation<br/>Ser396/Thr231/Ser202"]
    D["Tau Detachment<br/>Microtubule Destabilized"]
    E["Tau Oligomers<br/>Paired Helical Filaments"]
    F["Neurofibrillary Tangles<br/>Intraneuronal Inclusions"]
    G["Axonal Transport Failure<br/>Synaptic Dysfunction"]
    H["Neurodegeneration<br/>Tauopathy Spread"]
    A --> B
    B --> C
    C --> D
    D --> E
    E --> F
    D --> G
    G --> H
    F --> H
    style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
    style C fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
    style H fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a

⚖️ Evidence

⚖️ Evidence Matrix5 supports2 contradicts
Supports
Tau interactome maps synaptic and mitochondrial processes associated with neurodegeneration.
Cell2022PMID:35063084medium
Supports
Tau filaments with the Alzheimer fold in human MAPT mutants V337M and R406W.
Nat Struct Mol Biol2025PMID:40044789medium
Supports
MAPT mutations, tauopathy, and mechanisms of neurodegeneration.
Lab Invest2019PMID:30742061medium
Supports
Endolysosomal impairment by binding of amyloid beta or MAPT/Tau to V-ATPase and rescue via the HYAL-CD44 axis in Alzheimer disease.
Autophagy2023PMID:36843263medium
Supports
Tau-targeting antisense oligonucleotide MAPT(Rx) in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial.
Nat Med2023PMID:37095250medium
Contradicts
Epigenetic age acceleration shows inconsistent moderation of amyloid-to-tau conversion.
PubMed: Eissman et al. 2025, Alzheimer's & Dementi2024PMID:40439808
Abstract
Effect sizes are small and heavily dependent on baseline amyloid burden.
Contradicts
Multi-clock ensemble discordance lacks validation in independent cohorts.
PubMed: Teschendorff & Horvath 2025, Nat Rev Genet2025PMID:39806006
Abstract
Overfitting in discovery cohorts leads to inflated effect size estimates.
📖 Linked Papers (15)Export BibTeX ↗
Epigenetic age acceleration and allergic diseases: a bidirectional two-sample Mendelian randomization study.
Clin Epigenetics (2025) · PubMed:40618086 ↗
No figures
Childhood Asthma and Allergy Are Related to Accelerated Epigenetic Aging.
Allergy (2025) · PubMed:40346984 ↗
No figures
Tau filaments with the Alzheimer fold in human MAPT mutants V337M and R406W.
Nature structural & molecular biology (2025) · PubMed:40044789 ↗
No figures
Tau filaments with the Alzheimer fold in human MAPT mutants V337M and R406W.
Nature structural & molecular biology (2025) · PubMed:40044789 ↗
No figures
DNA methyltransferase 1 (DNMT1) promotes cyst growth and epigenetic age acceleration in autosomal dominant polycystic kidney disease.
Kidney Int (2024) · PubMed:38782200 ↗
No figures
Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial.
Nature medicine (2023) · PubMed:37095250 ↗
No figures
Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial.
Nature medicine (2023) · PubMed:37095250 ↗
No figures
Endolysosomal impairment by binding of amyloid beta or MAPT/Tau to V-ATPase and rescue via the HYAL-CD44 axis in Alzheimer disease.
Autophagy (2023) · PubMed:36843263 ↗
No figures
Endolysosomal impairment by binding of amyloid beta or MAPT/Tau to V-ATPase and rescue via the HYAL-CD44 axis in Alzheimer disease.
Autophagy (2023) · PubMed:36843263 ↗
No figures
Tau interactome maps synaptic and mitochondrial processes associated with neurodegeneration.
Cell (2022) · PubMed:35063084 ↗
No figures
Tau interactome maps synaptic and mitochondrial processes associated with neurodegeneration.
Cell (2022) · PubMed:35063084 ↗
No figures
A systematic review of biological, social and environmental factors associated with epigenetic clock acceleration.
Ageing Res Rev (2021) · PubMed:33930583 ↗
No figures

🏥 Translation

🧬 3D Protein Structure — MAPT

🧬 PDB 5O3L Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

🧠 GTEx v10 Brain ExpressionJSON

Median TPM across 13 brain regions for MAPT from GTEx v10.

Cerebellum209 Cerebellar Hemisphere199 Cortex152 Frontal Cortex BA9146 Anterior cingulate cortex BA24101 Hypothalamus86.4 Amygdala73.5 Nucleus accumbens basal ganglia72.2 Hippocampus72.1 Caudate basal ganglia64.7 Putamen basal ganglia58.1 Substantia nigra56.8 Spinal cord cervical c-149.2median TPM (GTEx v10)

💉 Clinical Trials

No clinical trials data linked to this hypothesis yet.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for MAPT →

No DepMap CRISPR Chronos data found for MAPT.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend
Stable
7d Momentum
▲ 0.0%
Volatility
High
0.1895
Events (7d)
1
Price History
▲9.1%

💾 Resource Usage

LLM Tokens
424,159
$1.5538
API Calls
36
Total Cost
$1.5538

🔮 Predictions

🔎 Predictions vs Observations2 predictions · 0 with recorded observations
PredictionPredictedObservedStatusConf
IF the clock-threshold model is causal rather than correlative, THEN lowering senescence-associated methylation age in amyloid mouse models will reduce hippocampal phospho-tau burden by >=20% within 1Intervention lowers hippocampal p-tau immunoreactivity by >=20% versus control while amyloid plaque area changes by <10%.— no observation —pending0.52
IF epigenetic age acceleration moderates amyloid-to-tau conversion, THEN amyloid-positive older adults above a +5 year methylation-age threshold will accumulate tau PET signal at least 25% faster overAnnual regional tau PET SUVR slope is >=25% higher in the high epigenetic-age group after covariate adjustment.— no observation —pending0.64
🔮 Falsifiable Predictions (2)
pendingconf 64%
IF epigenetic age acceleration moderates amyloid-to-tau conversion, THEN amyloid-positive older adults above a +5 year methylation-age threshold will accumulate tau PET signal at least 25% faster over 24 months than amyloid-positive peers below the threshold.
Predicted outcome: Annual regional tau PET SUVR slope is >=25% higher in the high epigenetic-age group after covariate adjustment.
Falsification: Tau PET slope differs by <10% between high and low epigenetic-age amyloid-positive groups.
pendingconf 52%
IF the clock-threshold model is causal rather than correlative, THEN lowering senescence-associated methylation age in amyloid mouse models will reduce hippocampal phospho-tau burden by >=20% within 16 weeks without changing amyloid plaque load.
Predicted outcome: Intervention lowers hippocampal p-tau immunoreactivity by >=20% versus control while amyloid plaque area changes by <10%.
Falsification: p-tau reduction is <10% or occurs only with a proportional amyloid plaque reduction.
View on SciDEX ↗